From market access, government policy, patient services, and marketing and sales strategies, John Hess provides over 25 years of North American experience holding senior roles in oncology and cardiovascular franchises in both start-up and large, multinational organizations.
Before joining Chiesi Global Rare Disease, John was the ApoPharma Director of Commercial Operations for the Americas. John worked for Daiichi Sankyo for 19 years, where he served as the National Director of Oncology and launched Zelboraf® (vemurafenib). In this role, he also served as a member of the pexidartinib and tivantinib global new product teams. In 1996, John was selected as a “charter member” to launch Camptosar® (irinotecan) and led commercial teams through multiple mergers and acquisitions.